Neoplastic cells exhibit higher oxidative stress compared to normal cells; however, antioxidants based clinical trials have mostly failed. Another attractive therapeutic approach is to further increase the oxidative stress in cancer cells leading to cell death.
| INTRODUCTION
Prostate cancer (PCa) is the most common cancer in American men after the skin cancer. According to American Cancer Society estimates, in the year 2016, approximately 180 890 new cases of PCa will be diagnosed in the United States together with about 26 120 deaths; and mortality in American men due to PCa is second only to lung cancer. 1 PCa treatment includes hormonal ablation or androgen deprivation therapy (ADT), which is initially effective in almost all cases, but most of the patients eventually develop ADT resistance leading to castrationresistant PCa (CRPC) that is very aggressive. 2 Mechanistic studies suggest an association between oxidative stress and CRPC development, where PCa cells endogenously produce higher amounts of reactive oxygen species (ROS) promoting cell proliferation and genetic instability, a pre-requisite for cancer development and progression. [3] [4] [5] [6] ROS, generated inside the cells as by-product of normal metabolism, could cause tissue injury and DNA damage but in normal cells, a dynamic balance is maintained between ROS level (pro-oxidant) and antioxidant proteins and enzymes. However, with the age this balance shifts toward pro-oxidant resulting in a chronic increase in ROS. [7] [8] [9] Based upon these observations, in the past, several studies have focused on using anti-oxidants for both preventive and therapeutic approaches in the management of PCa. 10 however, these clinical trials failed to establish any relationship between overall PCa risk and dietary anti-oxidant consumption.
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On the contrary, patient's follow-up in SELECT trial showed a significant increase in numbers of prostate cancer in men who took vitamin compared to men on placebo. 15 Along with the failure of several antioxidants, there is plethora of the literature suggesting that elevated intracellular ROS level provides cancer cells an aggressive phenotype; however, ROS levels above a particular threshold could be deleterious to cancer cells. 3, 16 Therefore, recent research efforts have also focused onto increase ROS production in cancer cells via compounds displaying pro-oxidant properties. [17] [18] [19] [20] Importantly, compared to normal prostate epithelial cells, PCa cells generate higher amounts of ROS making them more prone to ROSinduced damages; enhanced ROS levels trigger pro-apoptotic signaling pathways as the anti-oxidant defense mechanisms are already compromised in these cancer cells. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In this regard, several dietary agents including grape seed extract (GSE) have been identified to cause apoptotic cell death in cancer cells by inducing oxidative stress. 3, [17] [18] [19] [20] [31] [32] [33] [34] [35] GSE is a naturally occurring dietary agent with proven potential against various malignancies, including PCa. 36 Studies in our laboratory have identified procyanidin B2 3,3″-di-O-gallate (B2G2) as the most active constituent of GSE, and we have shown that B2G2 causes cell growth inhibition and apoptotic cell death in human PCa
LNCaP, C4-2B, DU145, and PC-3 cells. [37] [38] [39] [40] However, B2G2's mechanism(s) of action that causes cell death has not been elucidated, which is important in order to develop this promising molecule as an anti-cancer agent against PCa. Therefore, the focus of present study was to examine and establish the molecular mechanism underlying ROS generation and its role in B2G2-induced cell death in human PCa cells.
| MATERIALS AND METHODS

| Cell lines and reagents
Human PCa LNCaP (androgen dependent) and 22Rv1 (androgen independent) cells were purchased from ATCC (Manassas, VA) and maintained in RPMI1640 media supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin and 10% FBS. was synthesized according to our previously published methods.
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B2G2 stock solution was prepared in DMSO and diluted in culture media to achieve the experimental concentrations. An equal amount of DMSO (vehicle) was present in each treatment, including control which did not exceed 0.1% (v/v). At the end of each treatment time, cells were collected and total cell number and dead cell percentage were determined using a hemocytometer after trypan blue staining.
| Cell viability assay
| Cellular ROS measurement
For the estimation of ROS in LNCaP and 22Rv1 cells, 3.0 × 10 4 cells/ well were plated in black 96-well plates with a clear bottom and, one day later, cellular monolayers were washed once with phenol red free RPMI1640 and subsequently stained (20 μM DCFDA; 45 min, 37°C).
After washing the cells once with phenol red free RPMI1640, cells were treated with B2G2 (50 μM) and relative fluorescence intensity was measured at 1, 3, 6, 9, 12, and 24 h in a multi-well plate reader (Molecular Devices, Sunnyvale, CA) using SoftMax software at an excitation and emission wavelengths of 485 and 535 nm, respectively. To establish the direct effect of B2G2 on mitochondrial complex III activity, mitochondria were isolated from naïve LNCaP cells and 100 μg mitochondrial fractions were incubated with different concentrations of B2G2 (10-50 μM) and complex III activity was measured and represented as described above. Antimycin A (3.0 μM), a known inhibitor of mitochondrial complex III activity, was used as the positive control.
| Immunoblotting
LNCaP cells were treated with different concentrations of B2G2
for the indicated time points and total cell lysates were prepared in non-denaturing lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1.0 mM ethylene diamine tetra acetic acid, The individual resistant clones were picked and grown separately and maintained in the same selection medium.
| MAP kinase phosphatase activity assay
To assess the MAP kinase phosphatase activity, we first immobilize The immobilized p-ERK2 was separated into six equal parts and incubated (1 h, 37°C) with 20 μg protein lysates prepared above.
Again, the agarose beads were pelleted by centrifugation (3000g, 2 min) and washed twice with phosphatase activity buffer and resuspended in 20 μL 2X SDS sample buffer, resolved on 8% SDS-PAGE and analyzed for p-ERK2 using anti-p-ERK1/2 antibody by immunoblotting as described above.
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| Statistics
All values are shown as mean ± standard error of mean (SEM).
Differences in parameters between treatments were analyzed by ANOVA followed by Tukey post hoc analysis and a P-value of ≤0.05
was considered as statistically significant.
3 | RESULTS
| B2G2-induces cell death in human PCa cells via increasing oxidative stress
Earlier, we have reported the cytotoxic effect of B2G2 against human PCa cells LNCaP, 22Rv1, C4-2B, DU145, and PC3 cells. androgen-dependent malignancy and mutation in AR is very common in PCa patients, 43 we chose LNCaP cells which harbor T877A mutation for our further mechanistic studies.
| NAC reverses B2G2-induced ROS generation and cell death in LNCaP cells
To demonstrate that B2G2-induced LNCaP cell death was due to ROS Overall, these results clearly suggest that B2G2 has pro-oxidant effects in human PCa cells and exerts its cytotoxic effects by generating ROS.
| Effect of NAC on B2G2-induced mitochondrial superoxide production and MMP loss in LNCaP cells
Mitochondria and NADPH oxidase (NOX) system are considered as major sources of ROS generation. [45] [46] [47] [48] Therefore, in order to identify the source of ROS following B2G2 treatments, we first assessed the effect of B2G2 on NOX activity in LNCaP cells and observed no change in its activity at 6 h (data not shown), a time-point when B2G2
treatment causes highest ROS generation as shown in Figure 1D . This ruled out NOX role in B2G2-induced ROS production in LNCaP cells.
Next, we analyzed the effect of B2G2 treatment on mitochondrial superoxide generation using the mitochondria specific Mitosox red dye. As shown in Figure 2A , B2G2 treatment caused ∼2-fold increase in mitochondrial superoxide levels at 6 h which was only partially affected by NAC pre-treatment. Since, mitochondrial superoxide has been reported to depolarize MMP, we next assessed the effect of B2G2 treatment on MMP. As presented in Figure 2B , B2G2 treatment significantly reduced the MMP at 6 h that was also not affected by NAC pre-treatment. Furthermore, depolarization of MMP has been reported to cause a decrease in ATP production, and as shown in 
| B2G2 inhibits mitochondrial complex III activity
The primary source of superoxide ion in mitochondria occurs via mitochondrial electron transport chain (ETC) complexes as electrons may leak from these complexes and react with oxygen to form superoxide ions. 49 Earlier studies suggest that mitochondrial OXPHOS complexes I and III are the major source of leaked electrons and thus superoxide generation. 46, 49 Furthermore, our group recently reported that GSE induces mitochondrial superoxide generation in human head and neck cancer cells by inhibiting the activity of mitochondrial complex III. 19 Our results also showed that B2G2 treatment significantly inhibited complex III activity in LNCaP cells with no effect on complex I activity at all the tested time points (1, 3, and 6 h; Figures 2D and 2E) , which was consistent with increased levels of ROS At the end of each time point, ROS generation in terms of DCF (arbitrary fluorescence unit) was measured as described in the section 2. E-G, LNCaP cells were treated with NAC (10 mM) 15 min prior to B2G2 (50 μM) treatment and images were captured at the end of the experiment (24 h) and representative photographs are shown (F). In this experiment, ROS generation was measured at 6 h (G) and total cell number and percentage of cell death were determined via trypan blue assay at 24 h (H). In each case, data are expressed as mean ± SEM (n = 3). *P < 0.05, significant with respect to control group; # P < 0.05, significant with respect to the B2G2-treated group at 1 h and onward ( Figure 1D ). In addition, in order to assess whether B2G2 inhibits complex III activity via direct interaction, we isolated mitochondria from naïve LNCaP cells and incubated with various concentrations of B2G2 and then assayed for complex III activity. As shown in Figure 2F , B2G2 directly inhibited complex III activity in a dose dependent manner. Overall, these results support the notion that inhibition of complex III activity by B2G2 could be the primary cause of pro-oxidant effects of B2G2 in LNCaP cells.
| B2G2 activates ERK1/2 in LNCaP cells
It is well established that ROS-dependent sustained activation of ERK MAP kinases may be one of the probable reasons of its growth inhibitory effects. Figure 1H ). These results strongly suggest that B2G2-induced sustained ERK1/2 activation could be a key molecular event in its cytotoxic effects in LNCaP cells.
| B2G2 strongly inhibits MAP kinase phosphatase 3 activity in LNCaP cells
As mentioned in the introduction that ROS-induced inhibition of MKPs may leads to sustained activation of ERK, we next analyzed MKP1, 2, FIGURE 2 Effect of B2G2 on mitochondrial superoxide generation, mitochondrial membrane potential, ATP levels and activities of mitochondrial complexes I and III. A and B, LNCaP cells were treated with B2G2 (50 μM) with or without NAC (10 mM) for 6 h and mitochondrial superoxide generation was measured using MitoSox red dye (A); and mitochondrial membrane potential was measured using JC-1 dye (B). C, LNCaP cells were treated with different doses of B2G2 (30, 40, and 50 μM) and ATP level was measured after 6 h using an ATP assay kit. D and E, LNCaP cells treated with B2G2 (50 μM), mitochondria isolated after 1, 3, and 6 h and analyzed for mitochondrial complexes I and III activity. F, Mitochondria were isolated from naïve LNCaP cells and incubated with different concentrations of B2G2 (10-50 μM) and mitochondrial complex III activity was measured. Mitochondria treated with 3 μM antimycin (AA) served as positive control in this experiment. In each case, data are expressed as mean ± SEM (n = 3). *P < 0.05, significant with respect to control group and 3 protein levels in LNCaP cells following B2G2 treatment at 1, 3, 6, and 24 h. As shown in Figure 4A , B2G2 treatment only decreased the MKP3 expression at 3, 6, and 24 h, but not MKP1 and 2. Earlier reports suggest that MKPs contain a protein tyrosine phosphatase (PTP) domain with cysteine residues which could be oxidized by ROS resulting in MKP inactivation. 52 ,53 Therefore, we next assessed the effect of B2G2 on MKP activity using purified p-ERK2 as a substrate.
As presented in Figure 4B , de-phosphorylation of p-ERK2 was inhibited following B2G2 treatment suggesting an inhibition of MKP activity. Importantly, NAC pre-treatment restored the MPK activity inhibited by B2G2 treatment ( Figure 4B ). These results clearly suggested that B2G2-induced ROS generation activates ERK by inhibiting MKPs activity.
As only MKP3 was observed to be down regulated following B2G2 treatment, we over-expressed MKP3 in LNCaP cells ( Figure 4C Membranes were stripped and re-probed for total ERK1/2 and β-actin. C and D, LNCaP cells were treated with PD98059 (10, 25, and 50 μM) 15 min prior to B2G2 (50 μM) treatment and whole cell lysates were prepared at 24 h post-treatment and analyzed for p-ERK1/2 and cleaved PARP (cl PARP); membranes were stripped and re-probed for total ERK1/2 and β-actin (C); at the same time-point total cell number and percentage cell death were also determined by trypan blue exclusion assay (D). Data are expressed as of mean ± SEM (n = 3) for each treatment. *P < 0.05, significant with respect to control group. # P < 0.05, significant with respect to the B2G2-treated group. E, LNCaP cells were treated with NAC (10 mM) 15 min prior to B2G2 (50 μM) treatment, whole cell lysates were prepared at 6 and 9 h post-treatment and analyzed for p-ERK1/2 by immunoblotting. Membranes were stripped and re-probed for total ERK1/2 and β-actin. F, LNCaP cells were treated with NAC (10 mM) or compound C (20 μM) prior to B2G2 (50 μM) treatment, whole cell lysates were prepared at 24 h and analyzed for cl PARP. Membrane was stripped and re-probed for β-actin Figure 2C ). Therefore, we further assessed the effect of B2G2 on AMPK activation, a biomarker for cellular energy status. As shown in Figure 5A , AMPKα phosphorylation (Thr172) was enhanced in LNCaP cells at 6, 9, and 24 h following B2G2 treatment; and NAC pretreatment inhibited the AMPKα phosphorylation. In addition to
analyzing AMPKα phosphorylation levels, we also analyzed LC3B-II/ LC3B-1 ratio in LNCaP cells following B2G2 treatment with the rationale that higher LC3B cleavage is one of the hallmarks of autophagy and LC3B-II/LC3B-1 ratio was found to be increased in B2G2-treated LNCaP cells at 6 and 9 h ( Figure 5B ). It has been reported that ERK1/2 could activate AMPKα phosphorylation in mouse hypothalamic GT1-7 cells. 54 Therefore, we assessed the effect of MEK inhibitor PD98059 on AMPKα phosphorylation. As shown in Figure 5C , pre-treatment of PD98059 had no significant effect on B2G2-induced AMPKα phosphorylation. These results supported the notion that ERK1/2 is not involved in AMPKα activation. Next, to assess the involvement of AMPKα in B2G2-induced growth inhibition and death in LNCaP cells, we pre-treated LNCaP cells with compound C, a specific pharmacological AMPK inhibitor. As presented in Figure 5D , compound C significantly reversed the B2G2-induced cell growth inhibition and cell death; and as shown above in Figure 3F , compound C completely reversed the B2G2-induced PARP cleavage.
These results suggested that along with ERK activation, AMPK activation is also an important event in B2G2-induced cytotoxicity in ; complexes I and III have been previously identified as the major sites of this electron leakage. 46, 49 Earlier studies with antimycin A (a specific complex III inhibitor), GSE, benzyl isothiocyanate (BITC) and phenyl isothiocyanate (PITC) showed that inhibition of complex III leads to intracellular ROS generation in various cancer cells. [17] [18] [19] 55 Likewise, in the present study, B2G2 was found to significantly inhibit complex III activity with no effect on complex I activity; and thus complex III is the whereas a sustained activation seems to relate with apoptotic cell death. 56 In the present study, we observed that B2G2-mediated ERK1/2 activation was sustained even after 24 h. ERK1/2 role in B2G2-induced cell death was further supported by the finding that MEK inhibitor PD98059 pre-treatment reversed the B2G2-induced cell death.
FIGURE 5 B2G2 activates AMPK through MKP3 inhibition and causes cell death in LNCaP cells. A, LNCaP cells were treated with NAC (10 mM) 15 min prior to B2G2 (50 μM) treatment, whole cell lysates were prepared at 6 and 9 h post-treatment and analyzed for p-AMPKα by immunoblotting. Membranes were stripped and re-probed for total AMPKα and β-actin. B, LNCaP cells were treated with B2G2 (50 μM), whole cell lysates were prepared at 6 and 9 h time points and analyzed for LC3B-I/II via immunoblotting. Membranes were stripped and reprobed for β-actin. C, LNCaP cells were treated with PD98059 (10, 25, and 50 μM) 15 min prior to B2G2 (50 μM) treatment, whole cell lysates were prepared at 24 h post-treatment and analyzed for p-AMPKα by immunoblotting. Membranes were stripped and re-probed for total AMPKα and β-actin. D, LNCaP cells were treated with compound C (20 μM) 15 min prior to B2G2 (50 μM) treatment and total cell number and percentage cell death were determined by trypan blue exclusion assay at the 24 h time point. Data are expressed as of mean ± SEM (n = 3) for each treatment. *P < 0.05, significant with respect to control group; # P < 0.05, significant with respect to B2G2-treated group. E, LNCaP-VC and LNCaP-MKP3 cells were treated with compound C (20 μM) 15 min prior to B2G2 (50 μM) treatment, whole cell lysates were prepared after 24 h and analyzed for p-AMPKα and cleaved PARP by immunoblotting. Membranes were stripped and re-probed for total AMPKα and β-actin. F, In the same experiment, total cell number and percentage cell death were also determined via trypan blue exclusion assay after 24 h. Data are expressed as of mean ± SEM (n = 3) for each treatment. *P < 0.05, significant with respect to control group; # P < 0.05, significant with respect to B2G2-treated group ROS causes sustained ERK1/2 activation and one of the mechanisms is through inactivation and degradation of protein phosphatases. 53, 57, 58 Protein phosphatases for MAP kinases are dual specificity phosphatases also called MAPK phosphatases (MKPs) and negatively regulate the MAPK signaling by dephosphorylating both threonine/tyrosine residues within the activation loop of MAPK. 58 Among MKPs, MKP1, 2, and 3 are reported to regulate the ERK1/2 activation negatively. 59 Our results showed that B2G2 down regulates the expression of MKP3 but not MKP1 and MKP2 along with its ability to inhibit overall MKP activity. These MKPs contain cysteine residues in their active domain which are redox sensitive and ROS can oxidize these residues leading to inhibition of their activity 53, 58 ; our results also illustrated that NAC pre-treatment restores B2G2-inhibited MKP activity. Furthermore, we also show that B2G2 effects are compromised in MKP3 overexpressing LNCaP cells; thereby, confirming the MKP3 role in B2G2-induced ERK1/2 activation and cell death.
One of the major observations from the current study is that neither pre-treatment with MEK inhibitor PD98059 nor overexpression of MKP3 completely reversed the B2G2-induced cell death in LNCaP cells. In this regard, we also observed that B2G2 treatment decreased the ATP level which could lead to AMPKα activation, thereby activating an additional pathway contributing toward B2G2-induced cell death and working in tandem with ERK1/ 2 activation. Our results illustrated that B2G2 induces phosphorylation of the α-catalytic subunit of AMPK which may be due to both energetic stress and oxidative stress. AMPK is a highly conserved cellular energy sensor and primarily activated by an increased AMP/ ATP ratio due to lowered ATP levels, that is, energetic stress. In addition, another mode of AMPK activation is ROS-mediated S-glutathionylation of cysteine residues within the α-catalytic subunit of AMPK, that is, oxidative stress. 60 The involvement of ROS in B2G2-induced AMPKα activation was confirmed by the observation that pre-treatment with NAC inhibits AMPKα phosphorylation. In addition, pre-treatment of LNCaP cells with AMPK inhibitor compound C was found to reverse B2G2-induced growth inhibition and cell death, which further confirmed the role of AMPK in the observed B2G2-induced biological effects. Previous studies also reported the activation of AMPK in response to energetic and oxidative stress leading to apoptotic cell death in cancer cells and is considered as an important target for cancer therapy. 60 Similarly, Kaur et al have shown that AMPKα inhibition reversed bitter melon juice-induced caspase 3 activation in human pancreatic BxPC-3 cells. 61 Lastly, AMPK inhibition in MKP3 overexpressing LNCaP cells almost completely reversed the B2G2-induced cell death, further supporting the role of ROS-mediated AMPK and ERK1/2 activation as a probable mechanism for B2G2 efficacy against PCa cells.
In conclusion, we have demonstrated that B2G2 possesses strong pro-oxidant property and targets mitochondrial electron transport complex III leading to ROS generation causing oxidative and energetic stress in human prostate LNCaP cells. Molecular studies revealed that B2G2 inhibits MKP3 activity resulting in sustained activation of ERK1/2 and AMPKα; and this modulation in redox signaling underlies B2G2-induced biological effects in LNCaP cells (summarized in Figure 6 ). These promising findings need to be further validated in relevant in vivo PCa models for potential translational application.
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